Healthcare Industry News: INAMED
News Release - November 14, 2007
Kythera Biopharmaceuticals Appoints Industry Veteran as Vice President, Regulatory AffairsDeepak Chadha, MS, MBA, RAC Joins Kythera
A Growing Biopharmaceutical Company
LOS ANGELES--(HSMN NewsFeed)--Kythera Biopharmaceuticals, Inc. (“Kythera”) announced today the appointment of Deepak Chadha, MS, MBA, RAC as Vice President, Regulatory Affairs. Chadha will lead Kythera’s regulatory submissions and oversee regulatory projects covering Kythera’s expansive product pipeline.
Chadha brings to Kythera more than 13 years of experience in regulatory submissions and projects for drugs, biologics, medical devices and combination products. His most recent role was Vice President, Global Regulatory Affairs at Allergan Medical (formerly know as INAMED Corporation), where he helped build the Global Regulatory Affairs Department and was responsible for developing and implementing global regulatory strategies. Chadha led the group to successful submission and approval of aesthetic products in the U.S. and overseas. Prior to Allergan, Chadha held positions of increasing responsibility at Biomeasure Inc. (Ipsen) and Stryker Biotech in Massachusetts. At Biomeasure Inc., he oversaw the U.S. regulatory activities of Ipsen’s Botulinum Toxin Type-A development program for the aesthetic indication. Chadha’s regulatory experience encompasses preparation and successful submission of clinical and marketing applications to the FDA, the EMEA, as well as the regulatory agencies of the United Kingdom, Canada, Australia, and Japan among others.
Chadha holds a BS in Pharmaceutical Sciences from Berhampur University in Orissa, India, an MS in Pharmaceutics from Hamdard University in New Delhi, India, and an MBA in International Business from California State University, Dominguez Hills.
“Deepak joins Kythera at a critical time to lead key programs through the regulatory process both in the U.S. and globally,” said Patricia Walker, MD, PhD, Kythera’s Chief Medical Officer. “We are fortunate to have someone with such expertise in aesthetic drug and device development join our team. I am confident he will add immediate value in guiding submissions of key regulatory filings.”
Kythera is conducting multiple trials in the US, UK, and Australia on its lead product ATX-101 and is nearing completion of a trial in France on ATX-201.
“Kythera is fortunate to access Deepak’s robust regulatory experience,” said Keith Leonard, Kythera’s CEO. “We are preparing for multiple regulatory submissions as we move products through our pipeline, and Deepak’s knowledge of drug and device submissions will be key to moving Kythera closer to being a full commercial entity.”
About Kythera Biopharmaceuticals
Kythera Biopharmaceuticals is a privately held biopharmaceutical company focused on science and innovation in aesthetic medicine. The aesthetic medicine market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market. Kythera has clinical-stage programs in adipolysis, pigmentation modulation, and actinic keratosis, and preclinical-stage research programs in photoaging, dermal contouring, and topical neuromodulation.
For more information about Kythera, please visit the company’s Web site at www.kytherabiopharma.com.
Source: Kythera Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.